No Data
(LGVN) - Analyzing Longeveron's Short Interest
Express News | Longeveron Announces Closing of $9.0 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules
Why Longeveron (LGVN) Shares Are Down 15%
Why Domino's Pizza Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Express News | Longeveron Announces $9.0 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules
US stocks fluctuate | Longeveron rose nearly 2% before the market and received FDA approval for fast track design.
On July 18, Gelunhui reported that Longeveron (LGVN.US), a concept stock for Alzheimer's therapy, rose 1.79% before the market, reaching $3.97. According to the news, Lomecel-b has been granted a fast-track designation by the US FDA for the treatment of mild Alzheimer's disease. It is reported that investigational therapies designated as fast-track may be eligible for priority review if they meet certain criteria at the time of submission of the application to the FDA, and may undergo rolling FDA review.
No Data